WO2024156921 - PROTEASOMAL DEGRADATION OF PROTEINS
National phase entry is expected:
Publication Number
WO/2024/156921
Publication Date
02.08.2024
International Application No.
PCT/EP2024/052079
International Filing Date
29.01.2024
Title **
[English]
PROTEASOMAL DEGRADATION OF PROTEINS
[French]
DÉGRADATION PROTÉASOMIQUE DE PROTÉINES
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
DAELEMANS, Dirk
KWANTEN, Bert
Priority Data
23153630.1
27.01.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1947 | |
| EPO | Filing, Examination, Granting | 8360 | |
| Japan | Filing, Examination, Granting | 2026 | |
| South Korea | Filing, Examination, Granting | 1718 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,791
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to methods of identifying a small molecule that promotes ASB (Ankyrin repeat and SOCS box protein) mediated degradation of a target protein, comprising the step of: - providing in vitro conditions allowing the binding of a small molecule and the protein target, and - determining whether binding of the small molecule to the target protein results in the binding of an ASB protein to the target protein, wherein a small molecule that results in the binding of an ASB protein to a target protein with the small molecule, is a candidate medicinal compound for conditions wherein a target protein is to be degraded.[French]
L'invention concerne des méthodes d'identification d'une petite molécule qui favorise la dégradation médiée par ASB (répétition ankyrine et protéine de la boîte SOCS) d'une protéine cible, comprenant l'étape consistant à : - fournir des conditions in vitro permettant la liaison d'une petite molécule et de la cible protéique, et - déterminer si la liaison de la petite molécule à la protéine cible entraîne la liaison d'une protéine ASB à la protéine cible, une petite molécule qui conduit à la liaison d'une protéine ASB à une protéine cible avec la petite molécule, étant un composé médicinal candidat pour des conditions dans lesquelles une protéine cible doit être dégradée.